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Down syndrome (DS) is associated with intellectual disability and an ultra-high risk of
developing dementia. Informant ratings are invaluable to assess abilities and related
changes in adults with DS, particularly for those with more severe intellectual disabilities
and/or cognitive decline. We previously developed the informant rated Cognitive Scale
for Down Syndrome (CS-DS) to measure everyday cognitive abilities across memory,
executive function, and language domains in adults with DS, finding CS-DS scores are
a valid measure of general abilities, and are significantly lower for those with noticeable
cognitive decline compared to those without decline. To further test the validity of the
CS-DS in detecting changes associated with cognitive decline we collected longitudinal
data across two time points, approximately 1.5–2 years apart, for 48 adults with DS aged
36 years and over. CS-DS total scores (78.83 ± 23.85 vs. 73.83 ± 25.35, p = 0.042)
and executive function scores (46.40± 13.59 vs. 43.54± 13.60, p= 0.048) significantly
decreased between the two time points, with scores in the memory domain trending
towards a significant decrease (22.19 ± 8.03 vs. 20.81 ± 8.63, p = 0.064). Adults with
noticeable cognitive decline at follow-up showed a trend to significantly greater change in
total scores (7.81 ± 16.41 vs. 3.59 ± 16.79, p = 0.067) and significantly greater change
in executive function scores (5.13 ± 9.22 vs. 1.72 ± 9.97, p = 0.028) compared to
those without decline. Change in total scores showed significant correlations with change
in scores from other informant measures of everyday adaptive abilities and symptoms
associated with dementia, and participant assessment of general cognitive abilities (all
p < 0.005), while change in memory scores (R2 = 0.28, p = 0.001) better predicted
change in participant cognitive assessment scores than change in executive function
(R2 = 0.15, p= 0.016) or language (R2 = 0.15, p= 0.018) scores. These results suggest
informants may better detect changes in the executive function domain, while change
in informant rated memory scores best predicts change in assessed cognitive ability.
Alternatively, memory domain scores may be sensitive to changes across both early and
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late cognitive decline, whereas executive function domain scores are more sensitive to
changes associated with later noticeable cognitive decline. Our results provide further
support for the validity of the CS-DS to assess everyday cognitive abilities and to detect
associated longitudinal changes in individuals with DS.
Keywords: Down Syndrome, dementia, cognitive decline, informant rating, cognitive scale for Down Syndrome
(CS-DS)
INTRODUCTION
Down Syndrome (DS), caused by the triplication of chromosome
21, has a UK prevalence of approximately 1 in 1,000 live births
(1). DS is themost common genetic cause of intellectual disability
(ID), and is also associated with an ultra-high risk of developing
dementia due to Alzheimer’s disease (2); lifetime dementia risk
may be as high as 95% (3). There is large variability in these
phenotypes however, with ID severity varying from mild to
severe/profound, and the age of dementia onset varying from the
late 30 s to the 60 s (4, 5).
This variability in cognitive abilities and high rate of dementia
in individuals with DS poses a challenge to the development of
cognitive test batteries that are suitable for all individuals. While
several batteries have been developed for use in adults with DS
(5–9), some individuals are unable to complete tasks or perform
at floor level, in particular older adults who are showing cognitive
decline. For these individuals, informant ratings are invaluable
to assess abilities and related changes. Although previously
published questionnaires exist to assess symptoms related to
dementia (10–12), a lack of a dedicated informant measure
assessing everyday cognitive abilities suitable for the majority of
people with DS led us to develop the Cognitive Scale for Down
Syndrome (CS-DS) (13). The CS-DS focuses on abilities related
to memory, executive function, and language, as these are often
impaired in people with DS (14–18). We found the CS-DS is
suitable for use with a wide range of individuals with DS, showing
a range of scores and minimal floor and ceiling effects. It shows
high inter-rater and test-retest reliability, with scores correlating
well with measures of general abilities in adults without cognitive
decline, and lower scores for those with significant cognitive
decline compared to those without decline.
To further test the validity of the CS-DS in detecting changes
associated with cognitive decline in those with DS, we collected
longitudinal data with the CS-DS completed at two time points,
∼1.5–2 years apart, for adults with DS aged 36 years and over.
Here we present longitudinal analysis exploring changes in total
and domain scores over this time.
MATERIALS AND METHODS
Participants
Of the 128 adults with DS in the original CS-DS study (13), all
63 adults aged 36 years and over were contacted for a follow-up
assessment ∼1.5–2 years after their original assessment. Adults
aged 36 years and over were contacted for a follow-up assessment
due to the increased risk of cognitive decline in this age group,
based on previous studies investigating cognitive decline in adults
with DS and neuropathological studies indicating the presence
of Alzheimer’s disease pathology in the brains of almost all
adults with DS from the mid-30s (2); adults aged 35 and under
were not expected to show cognitive decline and so did not
have a follow-up assessment. All participants had originally
been recruited from across England from the LonDownS adult
cohorts; see Startin et al. (5) for full details of the cohorts and
assessment battery.
Assessment
Informants for participants with DS were asked to complete
the CS-DS (13) at both the original and follow-up assessments.
All informants knew the participant well, and were usually
relatives or paid carers. The CS-DS consists of 61 questions
with three options for informants to select from: never/rarely
true, sometimes true, or often/always true. Half the questions
are reverse phrased to reduce response bias, with scores of
0, 1, or 2 depending on the response (higher scores indicate
higher abilities). CS-DS total scores and scores for the memory,
executive function, and language domains were used in analysis.
In addition to informants completing the CS-DS, they
completed the short Adaptive Behavior Scale (short ABS) and the
Dementia Questionnaire for People with Learning Disabilities
(DLD). The short ABS assesses everyday adaptive abilities (with
higher scores indicating higher abilities) (19), while the DLD
assesses cognitive and social symptoms associated with dementia
(with higher scores indicating poorer abilities) (11). Participants
whomet vision and hearing thresholds [see Startin et al. (5)] were
administered the Kaufman Brief Intelligence Test 2 (KBIT-2), a
measure of general cognitive abilities (20); seven individuals were
not administered the KBIT-2 due to not meeting the vision or
hearing threshold. The KBIT-2 contains two subscales, a verbal
scale (verbal knowledge and riddle completion tests) and a non-
verbal scale (pattern completion test). Each test was started at
question 1 and stopped after four consecutive incorrect answers.
Total raw scores were used for analysis due to high floor effects
when converting to age adjusted IQ scores (5).
Informants were also administered the Cambridge
Examination of Mental Disorders of Older People with
Down’s Syndrome and Others with Intellectual Disabilities
(CAMDEX-DS) (21) to assess the presence or absence of
noticeable cognitive decline. Noticeable cognitive decline was
defined as decline occurring in the memory domain and in
either the other cognitive functions or personality and behaviour
domains (therefore indicating decline in multiple domains),
with the decline not co-occurring with other factors such
as depression.
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Statistical Analysis
We used SPSS version 22 for all analyses. Missing items on the
CS-DS were given a score of one (the median possible score)
when up to five answers were missing, while missing items on the
DLD were imputed for up to 15% of items within each domain
using the nearest integer to the mean value of completed scores
within that domain.
To determine whether CS-DS scores changed over time, we
first compared CS-DS scores at the two time points using paired
samples t-tests; total scores were compared, in addition to scores
for the memory, executive function, and language domains.
Given the presence of Alzheimer’s disease neuropathology in
adults with DS by the mid-30s (2, 22), cognitive decline may have
occurred in all assessed individuals, whether or not this had been
noticed by carers, and so analysis was performed across the whole
group to determine whether a significant change in scores had
occurred. In addition, as changes in CS-DS scores may be greater
in those with noticeable cognitive decline compared to those
without noticeable cognitive decline, we further compared score
changes between those with and without noticeable cognitive
decline at the second assessment while controlling for baseline
score using an ANCOVA. Again, total scores and scores for
the memory, executive function, and language domains were
compared. For all analyses values for η2 determined the overall
effect size of the time point in scores.
To assess the relationships between change in CS-DS total
score and change in scores from the short ABS, DLD, and KBIT-2
we performed correlational analysis using Pearson’s correlation.
To explore whether change in scores for the memory, executive
function, and language domains predicted cognitive decline as
assessed by change in KBIT-2 scores we performed regression
analyses, with separate regression models for each domain.
RESULTS
Of the original 63 participants aged 36 years and over with a
complete CS-DS at the original assessment, when contacted for
follow-up six were deceased and five refused or were unable to
take part. Two participants had developed advanced dementia,
being fully dependent on others, and so the questionnaire was
not completed as many questions were not applicable and
would have missing answers. Of the 50 follow-up questionnaires
completed, two contained more than five missing answers, and
so were excluded from analyses. A total of 48 participants were
therefore included in the longitudinal analyses. Forty seven
adults had genetically confirmed triplication of chromosome
21, with trisomy 21 in 44 individuals, a translocation in one
individual, and mosaic DS in two individuals. Considering the
presence of noticeable cognitive decline based on information
from the CAMDEX-DS, 29 participants (60.4%) showed no
cognitive decline at either time point, while 12 participants
(25.0%) showed cognitive decline at both time points. Four
participants (8.3%) showed cognitive decline at the second time
point but not the first, while three participants (6.3%) showed
cognitive decline at the first time point but not the second
[see Figure 1 for participant flow diagram and Table 1 for
demographic information and assessment scores for participants;
the full dataset for the study is available at Startin et al. (23)].
Comparing CS-DS scores at the two time points across all
participants, total scores were significantly lower at time 2
[t(47) = 2.09, p = 0.042, η
2
= 0.085, 95% CI (0.18, 9.82)]. Scores
for the executive function domain were significantly lower at time
2 [t(47) = 2.03, p = 0.048, η
2
= 0.080, 95% CI (0.02, 5.69)], while
scores for the memory domain trended to being significantly
lower at time 2 [t(47) = 1.90, p = 0.064, η
2
= 0.071, 95% CI
(−0.08, 2.83)] and there was no significant change in scores for
the language domain [t(47) = 1.33, p= 0.191, η
2
= 0.036, 95% CI
(−0.40, 1.94)].
Comparing CS-DS score changes between those with and
without noticeable cognitive decline at the follow-up assessment,
there was a trend to a significantly greater change in total
score for adults with noticeable cognitive decline [F(1, 45) = 3.53,
p = 0.067, η2 = 0.073]. Change in executive function score was
significantly greater for those with noticeable cognitive decline
[F(1, 45) = 5.17, p = 0.028, η
2
= 0.103], with no significant
difference in change in memory [F(1, 45) = 1.02, p = 0.318,
η
2
= 0.022] or language [F(1, 45) = 2.32, p = 0.135, η
2
= 0.049]
scores between the groups (Table 2).
Investigating the relationships between change in CS-DS
scores and change in scores from the short ABS, DLD, and KBIT-
2, change in CS-DS total score was significantly correlated with
change in scores for each of the other measures (Table 3). Change
in score for each of thememory, executive function, and language
domains independently predicted change in KBIT-2 scores,
with CS-DS memory score change predicting greater variance
in KBIT-2 score change (memory: R2 = 0.28, unstandardized
B= 1.23, 95%CI (0.55, 1.92), standardized beta= 0.53, p= 0.001;
executive function: R2 = 0.15, unstandardized B = 0.48, 95%
CI (0.09, 0.87), standardized beta = 0.39, p = 0.016; language:
R2 = 0.15, unstandardized B = 1.13, 95% CI (0.20, 2.05),
standardized beta= 0.39, p= 0.018).
DISCUSSION
We assessed the longitudinal change in CS-DS scores in adults
with DS aged 36 years and over across two time points,
∼1.5–2 years apart. Total scores showed a significant decrease
over this time, with scores in the executive function domain
also showing a significant decrease and scores in the memory
domain trending to a significant decrease. Change in total scores
trended to be significantly greater in those with noticeable
cognitive decline compared to those without noticeable cognitive
decline at the second time point, with scores in the executive
function domain only showing a significantly greater change
in those with noticeable cognitive decline. Change in CS-DS
total scores showed significant correlations with change in scores
for informant measures of adaptive abilities and symptoms
associated with cognitive decline, in addition to a participant
measure of cognitive abilities. Finally, we found that change in
score for the CS-DS memory domain better predicted change in
participant cognitive abilities compared to the executive function
or language domains.
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FIGURE 1 | Flow chart showing participants included in longitudinal analysis.
Our results provide further support for the validity of the CS-
DS as a tool to assess everyday cognitive abilities and associated
decline in people with DS. We previously showed that CS-
DS scores were lower for individuals with noticeable cognitive
decline compared to those without noticeable cognitive decline
(13). We have now extended this finding to show that the CS-DS
is sensitive to detect longitudinal decline in scores, with decline
in CS-DS scores associated with decline in abilities assessed using
informant questionnaires and participant assessment. These
changes are likely reflective of the changes adults with DS
undergo as they age; the development of dementia eventually
occurs in almost all adults (3), and it has been suggested that
a third of adults aged over 30 may show longitudinal cognitive
decline over 16months (24). Supporting the longitudinal changes
in CS-DS score detecting underlying changes associated with
cognitive decline, changes in CS-DS scores showed significant
correlations with changes in scores on the DLD, an informant
questionnaire assessing symptoms related to dementia. Although
the difference in score change for those with and without
noticeable cognitive decline at the second time point did not
reach significance, this was likely due to the small sample
size of individuals with decline. Future studies should further
explore this.
Our results also suggest the presence of noticeable cognitive
decline at the second time point as assessed by informant report
was associated with significantly greater decline in scores for the
executive function domain only. This may suggest informants
better detect changes in this domain compared to changes in the
memory or language domains. In contrast, longitudinal change in
scores for thememory domain better predicted change in directly
assessed cognitive abilities compared to changes in scores for
the executive function or language domains. This may suggest
changes in assessed cognitive ability are most strongly associated
with change on informant ratedmemory scores. It is also possible
these results may indicate different domains of the CS-DS are
able to detect changes at different stages of cognitive decline, with
changes in the memory domain being apparent across both early
and later stages of cognitive decline, and greater changes in the
executive function domain only being apparent when noticeable
cognitive decline has occurred. Similarly, our previous studies
investigating cognitive changes across the lifespan in people with
DS found changes in memory abilities assessed via either direct
participant assessment or informant report were more strongly
associated with the early stages of progression of dementia
than changes in executive functioning (25). Other studies have
suggested the earliest changes associated with cognitive decline in
DS are inmemory (26, 27), though some studies noted prominent
changes in executive functioning (24, 28). Understanding the
time course of cognitive changes with the development of
cognitive decline in DS is essential to aid in the diagnosis and
monitoring of dementia.
The use of additional time points in future studies, along
with larger samples, will allow further exploration of longitudinal
changes in CS-DS scores. This will allow a potential difference
in the change in score for those with and without noticeable
cognitive decline to be better determined, in addition to better
exploring whether CS-DS scores may be predictive of future
decline in individuals. Given the high prevalence of dementia
in people with DS, it is essential to detect the earliest signs
of cognitive decline to assist in the diagnosis of dementia
and to improve individuals’ prognosis through suitable health
care. Detecting these earliest changes requires longitudinal
assessments using measures sensitive to these changes. Larger
studies are needed to determine whether the CS-DS may
be suitable for this, and it will be essential to compare
changes in CS-DS score to changes in other relevant informant
questionnaires to determine which measures are most sensitive
to detecting changes at the earliest stage of cognitive decline; such
questionnaires include the CAMDEX-DS (21), the DLD (11),
the DSQIID (Dementia Screening Questionnaire for Individuals
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TABLE 1 | Demographic information and assessment scores for participants
included in longitudinal analysis.
Participants
Number 48
Age at first assessment 46.06 ± 6.94 (36, 64)
Sex 26 (54.2%) male, 22 (45.8%)
female
Pre-dementia level of ID 23 (47.9%) mild, 17 (35.4%)
moderate, 8 (16.7%) severe
Interval between CS-DS assessments
(months)
21.40 ± 2.05 (17, 24)
CS-DS total score time 1 78.83 ± 23.85 (23, 117)
CS-DS total score time 2 73.83 ± 25.35 (21, 118)
CS-DS total score change 5.00 ± 16.61 (−29, 38)
CS-DS memory score time 1 22.19 ± 8.03 (1, 32)
CS-DS memory score time 2 20.81 ± 8.63 (4, 32)
CS-DS memory score change 1.38 ± 5.01 (−7, 13)
CS-DS executive function score time 1 46.40 ± 13.59 (15, 68)
CS-DS executive function score time 2 43.54 ± 13.60 (16, 69)
CS-DS executive function score change 2.85 ± 9.76 (−18, 21)
CS-DS language score time 1 10.25 ± 4.36 (3, 18)
CS-DS language score time 2 9.48 ± 4.94 (1, 18)
CS-DS language score change 0.77 ± 4.02 (−9, 8)
Short ABS score change (n = 39) 6.23 ± 15.06 (−19, 55)
DLD cognitive score change (n = 43) −2.84 ± 7.49 (−24, 9)
DLD social score change (n = 45) −1.11 ± 7.82 (−33, 13)
KBIT-2 score change (n = 37) 2.65 ± 11.20 (−20, 38)
Values show mean ± standard deviation (minimum, maximum). CS-DS total scores and
scores for the executive function domain were significantly lower at time 2 compared
to time 1 [t(47) = 2.09, p = 0.042 and t(47) = 2.03, p = 0.048, respectively]. Scores
for the memory domain trended to being significantly lower at time 2 [t(47) = 1.90,
p = 0.064] and there was no significant change in scores for the language domain
[t(47) = 1.33, p = 0.191]. All comparisons were performed using paired samples t-tests.
CS-DS, Cognitive Scale for Down Syndrome; DLD, Dementia Questionnaire for People
with Learning Disabilities; ID, intellectual disability; KBIT-2, Kaufman Brief Intelligence Test
2; short ABS, short Adaptive Behavior Scale.
with Intellectual Disabilities) (12), and theDSDS (Dementia Scale
for Down Syndrome) (10). It is further possible that different
questionnaires may be useful in measuring decline at different
stages in the progression of dementia. Further, the identification
of potential CS-DS score cut-offs for single and longitudinal
assessments to detect cognitive decline in people with DS may
be of use in clinical settings. Given the wide variability in pre-
morbid level of ID in people with DS, longitudinal cut-offs or
those based on level of ID would be necessary for high sensitivity,
and larger studies will enable this.
The CS-DS was designed as an informant outcome measure
to assess cognitive abilities, and to detect changes in cognitive
abilities over time. Results presented here and in Startin et al. (13)
indicate the CS-DS is a valid informant measure for cognitive
abilities, and the CS-DS is sensitive to longitudinal cognitive
decline in adults aged 36 years and over. However, it should be
noted there is some overlap in the scores for those with and
without noticeable cognitive decline, which may be potentially
related to pre-morbid level of ID, and so the CS-DS alone is
TABLE 2 | Change in CS-DS scores for those with and without noticeable





CS-DS total score change 7.81 ± 16.41 3.59 ± 16.79
CS-DS memory score change 1.50 ± 4.84 1.31 ± 5.17
CS-DS executive function score change 5.13 ± 9.22 1.72 ± 9.97
CS-DS language score change 1.19 ± 3.62 0.56 ± 4.25
Values show mean ± standard deviation. CS-DS total score changes trended to being
significantly greater for adults with noticeable cognitive decline compared to those without
noticeable cognitive decline [F(1, 45) = 3.53, p = 0.067], with score changes for the
executive function domain being significantly greater for those with noticeable cognitive
decline [F(1, 45) = 5.17, p = 0.028], and no significant difference in score changes for the
memory or language domains [F(1, 45) = 1.02, p = 0.318 and F(1, 45) = 2.32, p = 0.135,
respectively] between the groups. All comparisons were performed using ANCOVAs with
baseline score included as a covariate. CS-DS, Cognitive Scale for Down Syndrome.
TABLE 3 | Correlations for CS-DS total score change with short ABS, DLD, and
KBIT-2 score changes.
CS-DS total score change
Short ABS score change 0.44, 0.005
DLD cognitive score change −0.48, 0.001
DLD social score change −0.50, <0.001
KBIT-2 score change 0.48, 0.003
Values show Pearson’s correlation coefficient, p-value. For the DLD higher scores are
associated with poorer abilities, for all other measures higher scores are associated
with higher abilities. CS-DS, Cognitive Scale for Down Syndrome; DLD, Dementia
Questionnaire for People with Learning Disabilities; KBIT-2, Kaufman Brief Intelligence Test
2; short ABS, short Adaptive Behavior Scale.
not suitable for diagnosing dementia. Instead, the CS-DS may
be useful as a screening questionnaire for possible cognitive
decline at an individual level in people with DS. It is also possible
the CS-DS is sensitive to detecting improvements in cognitive
abilities following interventions, and future studies are needed to
investigate this.
It should however be noted that a single informant
questionnaire is not able to assess all aspects of cognitive
abilities, instead such questionnaires are only able to provide
a broad measure of abilities. Some abilities, for example those
relating to specific modalities such as visuospatial and verbal
memory abilities, would be best measured by formal participant
assessment, providing participants are able to engage in such an
assessment, and it may not be appropriate to assess such abilities
via informant report. To fully explore all aspects of cognitive
abilities and associated changes in these in people with DS it
would therefore be essential to undertake a detailed cognitive
assessment with participants using a comprehensive cognitive
battery similar to previously published batteries (5–9), with
informant questionnaires such as the CS-DS complementing
this and providing useful information for individuals unable to
engage in assessment.
The main limitation of the current study is the relatively
modest sample size, with a small number of individuals with
noticeable cognitive decline. In particular, too few individuals
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in the present study developed noticeable cognitive decline
between the two time points for subgroup analysis. Larger
samples with multiple time points will allow for analysis
to determine whether scores on the CS-DS can predict
future decline. Another limitation was the use of another
informant questionnaire (the CAMDEX-DS) to define noticeable
cognitive decline for analyses, although the use of the KBIT-
2 to assess the relationship between changes in CS-DS and
KBIT-2 scores allowed us to assess change in cognitive
abilities in participants directly. Other limitations apply to
the CS-DS itself; the questionnaire may be unsuitable for
individuals with severe dementia, as shown by incomplete
questionnaires for such individuals. However, the CS-DS was
not designed to be sensitive to later changes with dementia, and
questionnaires based on the progression of dementia symptoms
already exist.
Our results suggest changes in scores on the CS-DS are a valid
measure to detect longitudinal changes in everyday cognitive
abilities consistent with cognitive decline in adults with DS.
Although larger, longer studies are needed to further evaluate this
and to determine the use of the CS-DS in predicting cognitive
decline, we suggest this questionnaire may be a useful addition to
test batteries to measure cognitive abilities and changes in these
in individuals with DS.
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